Cell Signaling Technology

Product Pathways - Akt Signaling

Phospho-GSK-3β (Ser9) (5B3) Rabbit mAb #9323

Applications Reactivity MW (kDa) Source Isotype
W IHC-P IF-IC H M (R) (Mk) 46 Rabbit IgG

Applications Key:  W=Western Blotting  IHC-P=Immunohistochemistry (Paraffin)  IF-IC=Immunofluorescence (Immunocytochemistry)
Reactivity Key:  H=Human  M=Mouse  R=Rat  Mk=Monkey
Species enclosed in parentheses are predicted to react based on 100% sequence homology. Species cross-reactivity is determined by Western blot.

Specificity / Sensitivity

Phospho-GSK-3β (Ser9) (5B3) Rabbit mAb detects endogenous levels of GSK-3β only when phosphorylated at Ser9. The antibody may cross-react weakly with the phosphorylated form of GSK-3α due to high sequence homology.

Source / Purification

Monoclonal antibody is produced by immunizing rabbits with a synthetic phosphopeptide (KLH-coupled) corresponding to residues around Ser9 of human GSK-3β.

Western Blotting

Western Blotting

Western blot analysis of extracts from NIH/3T3 cells, λ-phosphatase- or PDGF-treated, using Phospho-GSK-3β (Ser9) (5B3) Rabbit mAb (upper) or GSK-3β (27C10) Rabbit mAb #9315 (lower).

Western Blotting

Western Blotting

Western blot analysis of extracts from wild type (lanes 1,2), GSK-3α knock out (lanes 3,4) and GSK-3β knock out (lanes 5,6) mouse embryonic fibroblast cells (MEF), untreated or PDGF treated, using Phospho-GSK-3β (Ser9) (5B3) Rabbit mAb (upper) and GSK-3α/β Antibody (lower). (MEF wild type, GSK-3α knock out and GSK-3β knock out cells were kindly provided by Dr. Jim Woodgett, University of Toronto, Canada).

IHC-P (paraffin)

IHC-P (paraffin)

Immunohistochemical analysis of paraffin-embedded human breast carcinoma using Phospho-GSK3β (Ser9) (5B3) Rabbit mAb.


IHC-P (paraffin)

IHC-P (paraffin)

Immunohistochemical analysis using Phospho-GSK-3beta (Ser9) (5B3) Rabbit mAb on SignalSlide(TM) Phospho-Akt (Ser473) IHC Controls #8101 (paraffin-embedded LNCaP cells, untreated (left) or LY294002-treated (right)).

IHC-P (paraffin)

IHC-P (paraffin)

Immunohistochemical analysis of paraffin-embedded wild type (left) or GSK-3 beta knock out (right) MEF cell pellets using Phospho-GSK-3beta (Ser9) (5B3) Rabbit mAb. (MEF wild type, GSK-3alpha knock out and GSK-3beta knock out cells were kindly provided by Dr. Jim Woodgett, University of Toronto, Canada).

IF-IC

IF-IC

Confocal immunofluorescent analysis of wild type (left), GSK-3alpha knock out (center), or GSK-3beta knock out (right) MEF cells, FGF-treated (top) or phosphatase-treated (bottom) using Phospho-GSK-3beta (Ser9) (5B3) Rabbit mAb (green). Actin filaments have been labeled with DY-554 phalloidin (red). Blue pseudocolor = DRAQ5™ (fluorescent DNA dye). (MEF wild type, GSK-3alpha knock out and GSK-3beta knock out cells were kindly provided by Dr. Jim Woodgett, University of Toronto, Canada).


Background

Glycogen synthase kinase-3 (GSK-3) was initially identified as an enzyme that regulated glycogen synthesis in response to insulin (1). GSK-3 is a ubiquitously expressed serine/threonine protein kinase that phosphorylates and inactivates glycogen synthase. GSK-3 is a critical downstream element of the PI3 kinase/Akt cell survival pathway, and its activity can be inhibited by Akt-mediated phosphorylation at Ser21 of GSK-3α and Ser9 of GSK-3β (2,3). GSK-3 has been implicated in the regulation of cell fate in Dictyostelium, and is a component of the Wnt signaling pathway required for Drosophila, Xenopus and mammalian development (4). GSK-3 has been shown to regulate cyclin D1 proteolysis and subcellular localization (5).

  1. Welsh, G.I. et al. (1996) Trends Cell. Biol. 6, 274-279.
  2. Srivastava, A.K. and Pandey, S.K. (1998) Mol. Cell. Biochem. 182, 135-141.
  3. Cross, D.A. et al. (1995) Nature 378, 785-789.
  4. Nusse, R. (1997) Cell 89, 321-323.
  5. Diehl, J.A. et al. (1998) Genes Dev. 12, 3499-3511.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

Rabbit Monoclonals Produced Using Epitomics® Technology, U.S. Patent No. 5,675,063.

Product Pathways

Drug Discovery Tools

Featured Technologies

Protein Classes